An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients

Sixteen patients with thalassaemia major were treated with subcutaneous desferrioxamine (DF) 50 mg/kg/d, 5 consecutive days a week, for 8 weeks. Every other week the total dose was administered by 12 h infusion pump or by rapid injection of the same dose (25 × 2 mg/kg) twice a day. The two methods o...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-09, Vol.98 (3), p.601-602
Main Authors: Di Gregorio, Felicia, Romeo, Maria A., Pizzarelli, Giuseppe, Aiello, Giuseppa, Russo, Giuseppe
Format: Article
Language:English
Subjects:
Adolescent
Adult
beta-Thalassemia - drug therapy
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Deferoxamine - administration & dosage
desferrioxamine
Female
Ferritins - blood
Humans
Injections, Subcutaneous
iron overload
Male
Medical sciences
Pharmacology. Drug treatments
rapid infusion
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sixteen patients with thalassaemia major were treated with subcutaneous desferrioxamine (DF) 50 mg/kg/d, 5 consecutive days a week, for 8 weeks. Every other week the total dose was administered by 12 h infusion pump or by rapid injection of the same dose (25 × 2 mg/kg) twice a day. The two methods of DF administration produced no significant differences in urinary iron excretion. No significant changes in serum ferritin levels were observed at the end of the study. Compared with continuous infusion, rapid injection is equally efficacious, does not induce serious side‐effects, is better accepted by the patients, and can improve their compliance to the iron‐chelating therapy.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.2553072.x